menu
    • menu
    [{"orgOrder":0,"company":"Complement Therapeutics","sponsor":"Gimv","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Series A Financing","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Complement Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Complement Therapeutics \/ Gimv","highestDevelopmentStatusID":"4","companyTruncated":"Complement Therapeutics \/ Gimv"},{"orgOrder":0,"company":"Complement Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"mini-CR1","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Complement Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Complement Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Complement Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Complement Therapeutics

    Menu

    Complement Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Complement Therapeutics

                            United Kingdom arrow
                            Neuroscience
                            Not Confirmed

                            Complement Therapeutics

                            United Kingdom arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Exagamglogene Autotemcel

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Tri...

                            Details : Exagamglogene Autotemcel is a Cell & Gene Therapy drug candidate, which is currently being evaluated in IND Enabling clinical studies for the treatment of Geographic Atrophy-associated with Macular Degeneration.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            October 08, 2025

                            Lead Product(s) : Exagamglogene Autotemcel

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Complement Therapeutics

                            United Kingdom arrow
                            Neuroscience
                            Not Confirmed

                            Complement Therapeutics

                            United Kingdom arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Exagamglogene Autotemcel

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Gimv

                            Deal Size : $78.9 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Complement Therapeutics Secures €72 Million in Series A Financing to Advance Novel Therapies Targeting Compl...

                            Details : With the financing, CTx will continue the development and complete a Phase Ib clinical proof of concept of its lead product CTx001. CTx001 is a highly innovative AAV gene therapy for the treatment of Geograpic Atrophy (GA) secondary to dry age-related ma...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            April 17, 2023

                            Lead Product(s) : Exagamglogene Autotemcel

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Gimv

                            Deal Size : $78.9 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth